Navigation Links
HeartWare to Present at the 2011 Bank of America Merrill Lynch Health Care Conference
Date:5/6/2011

FRAMINGHAM, Mass., and SYDNEY, May 6, 2011 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to make an investor presentation at the Bank of America Merrill Lynch Health Care Conference at 10:40 a.m. Pacific Time (1:40 p.m. ET) on Tuesday, May 10, 2011.  The conference is being held May 10-12, 2011 at the Encore at Wynn in Las Vegas.

A live webcast of the Company's presentation at the conference will be available via a link provided at www.heartware.com.  An archived replay of the presentation will also be available shortly after the presentation time until May 27, 2011.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union.  The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant under a continued access protocol and destination therapy.  For additional information, please visit www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com
Phone: +1 508 739 0864


'/>"/>
SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare International Reports First Quarter 2011 Revenues of $18.0 Million; 68% Increase From $10.7 Million in First Quarter 2010
2. HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients
3. HeartWare Announces Presentations at The International Society of Heart and Lung Transplantation Annual Meeting
4. HeartWare International Receives Approval From the Therapeutic Goods Administration (TGA) in Australia
5. HeartWare to Present at the Barclays Capital 2011 Global Healthcare Conference
6. HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million; 71% Increase From $12.2 Million In Fourth Quarter 2009
7. HeartWare Receives Third Patient Allotment From FDA - Authorizing 94 Additional Patients - Under Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical Trial
8. HeartWare to Present at the 29th Annual J.P. Morgan Healthcare Conference
9. HeartWare Files PMA Application for FDA Approval of the HeartWare® Ventricular Assist System for a Bridge-to-Transplant Indication
10. HeartWare International, Inc. Announces Completion of Concurrent Public Offerings of Convertible Senior Notes and Common Stock
11. HeartWare International, Inc. Announces Pricing of Concurrent Public Offerings of Convertible Senior Notes and Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 2017 Research and Markets has announced the ... to their offering. ... The global gas chromatograph market to grow at a CAGR ... Global Gas Chromatograph Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
(Date:3/29/2017)... 29, 2017  Novartis announced today that the ... the company,s Biologics License Application (BLA) filing and ... chimeric antigen receptor T cell (CAR-T) therapy, in ... patients with B-cell acute lymphoblastic leukemia (ALL). This ... a CAR-T. The priority review designation is expected ...
(Date:3/29/2017)... Research and Markets has announced the addition of the ... Centers & Forecast" report to their offering. ... The South Korean Proton Therapy Market is expected ... The Untapped Proton Therapy Market for South Korea ... Proton Therapy plays an important role in delivering comprehensive cancer care ...
Breaking Medicine Technology:
(Date:3/29/2017)... Milwaukee, WI (PRWEB) , ... March 29, 2017 , ... ... as its exclusive provider of co-op eligible dealer websites for its network of more ... line of professional landscaping and agricultural equipment including rotary and flail mowers and cutters, ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... professional squash, announced it has enlisted New York City-based sports and entertainment marketing ... develop and procure sponsorship opportunities for the Professional Squash Association (PSA), which includes ...
(Date:3/29/2017)... ... March 30, 2017 , ... Grass pollen is the main cause of hay fever in ... The season for grass pollen runs from May to July each year; with the worst ... to do? HayMax™ allergen barrier balms ( http://www.haymax.us ) provide an effective defense against grass ...
(Date:3/29/2017)... Amherst, Massachusetts (PRWEB) , ... March 30, 2017 , ... ... has had great success and feedback from high school and college students who have ... is being held July 7-23 and YFI is now accepting applications for enrollment. ...
(Date:3/29/2017)... , ... March 30, 2017 , ... Sports Brand EXOUS ... brace, which retails normally at $29.97; for the remaining days of March, the price ... been reduced to a special price of just $10 (regular retail price $19.97). , ...
Breaking Medicine News(10 mins):